Prognostic Value of the Immunoscore Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment

The primary objective is to validate that the Immunoscore test (IS0 to IS4) is able to identify patients with high risk (IS 0-1) of relapse or death whichever occurs first among Stage III patients under oxaliplatin-based adjuvant therapy. Then the prognostic value of Immunoscore Colon to predict disease free survival (DFS) will be assessed in Stage III patients under Oxaliplatin treatment in each arm of the IDEA trial (6- months and 3-months treatment). Finally, the additive value of the Immunoscore test to stratify the DFS will be evaluated among standard clinical and biological parameters and tumor features.